A new experimental drug therapy has shown some promising signs of slowing down the progression of a type of brain cancer by more than 16 months on average.
French drug developer Servier Labratories released results of a new medication that may become one of the earliest targeted therapies for a type of brain tumor affecting adults under the age of 50.
The development is one of the first major advances in a field that has made little progress for decades, giving hope to cancer patients and their families worldwide.
The new drug, Vorasidenib, staved off cancer growth over twice as long than in patients not taking the drug, with many needing little additional treatment, according to a study in the New England Journal of Medicine….